Clinical-stage biotech possibly nearing phase I completionNascent Biotech is reportedly closing in on phase I trial completion. I am interested to see if it pulls back and how it interacts with the moving averages.
www.nascentbiotech.com
−0.0120 USD
−2.09 M USD
0.00 USD
89.08 M
About Nascent Biotech Inc.
Sector
Industry
CEO
Sean Carrick
Website
Headquarters
North Palm Beach
Founded
2014
FIGI
BBG000C1NCS1
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. It focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Its products include Pritumumab, CLNH5, and MultiPharm. The company was founded by Mark C. Glassy on March 3, 2014 and is headquartered in North Palm Beach, FL.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NBIO is 0.0500 USD — it has decreased by −1.19% in the past 24 hours. Watch Nascent Biotech Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Nascent Biotech Inc. stocks are traded under the ticker NBIO.
NBIO stock has fallen by −13.83% compared to the previous week, the month change is a −19.35% fall, over the last year Nascent Biotech Inc. has showed a −67.85% decrease.
NBIO reached its all-time high on Jul 24, 2015 with the price of 1.6200 USD, and its all-time low was 0.0303 USD and was reached on Sep 27, 2024. View more price dynamics on NBIO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NBIO stock is 12.44% volatile and has beta coefficient of 1.03. Track Nascent Biotech Inc. stock price on the chart and check out the list of the most volatile stocks — is Nascent Biotech Inc. there?
Today Nascent Biotech Inc. has the market capitalization of 8.18 M, it has decreased by −17.14% over the last week.
Yes, you can track Nascent Biotech Inc. financials in yearly and quarterly reports right on TradingView.
NBIO net income for the last quarter is −377.39 K USD, while the quarter before that showed −512.58 K USD of net income which accounts for 26.37% change. Track more Nascent Biotech Inc. financial stats to get the full picture.
No, NBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nascent Biotech Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Nascent Biotech Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Nascent Biotech Inc. stock shows the strong sell signal. See more of Nascent Biotech Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.